Description: GalMed Medical Research Ltd. researches and develops proprietary drugs for the treatment of lipid metabolism related diseases. The company has developed a series of proprietary fatty acid bile-acid conjugates (FABACs) which selectively inhibit the enzyme Stearoyl-CoA Desaturase (SCD1), a key regulator in lipid metabolism. It's flagship clinical compound Aramchol (arachidyl amido cholanoic acid), has the potential to modify several of the key disorders related to lipid metabolism, including fatty liver, gallstones, diabetes, hyperlipidemia, cancer, and alzheimer's disease. The company is based in Tel Aviv, Israel. GalMed Medical Research Ltd. operates as a subsidiary of Galmed International Ltd.
Home Page: www.galmedpharma.com
GLMD Technical Analysis
16 Tiomkin Street
Tel Aviv,
6578317
Israel
Phone:
972 3 693 8448
Officers
| Name | Title |
|---|---|
| Mr. Allen Baharaff | Co-Founder, Pres, CEO & Chairman |
| Mr. Guy Nehemya | COO & Data Protection Officer |
| Mr. Yohai Stenzler CPA | Chief Accounting Officer |
| Dr. Liat Hayardeny | Chief Scientific Officer |
| Mr. Doron Cohen | Chief Financial Officer |
| Ms. Yael Hollander | VP of Legal Affairs & Strategy |
| Ms. Shani Ganon | HR Mang. |
| Dr. Tali Gorfine | Medical Consultant |
| Mr. Niv Alon | Head of PMO |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4799 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-03-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |